Engineering of a macromolecular scaffold to develop specific protease inhibitors

Nature Biotechnology

Volumn 21, Issue 9, 2003, Pages 1063-1068

  Stoop, A Allart ^a   Craik, Charles S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; MACROMOLECULES;

MACROMOLECULAR INHIBITORS;

BIOTECHNOLOGY;

AMINO ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; ECOTIN; KALLIKREIN INHIBITOR; MATRIPTASE; PLASMA KALLIKREIN; PROTEINASE INHIBITOR; SERINE PROTEINASE; THROMBIN; UNCLASSIFIED DRUG; UROKINASE;

ADAPTATION; ARTICLE; CRYSTAL STRUCTURE; DISSOCIATION; EQUILIBRIUM CONSTANT; GENE LIBRARY; GENETIC VARIABILITY; MACROMOLECULE; MUTATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SURFACE PROPERTY;

AMINO ACID SEQUENCE; ESCHERICHIA COLI PROTEINS; FEASIBILITY STUDIES; MACROMOLECULAR SUBSTANCES; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MUTAGENESIS, SITE-DIRECTED; PERIPLASMIC PROTEINS; PLASMA KALLIKREIN; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

EID: 0042861481     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt860     Document Type: Article

References (49)

1. Rawlings, N.D. Introduction: family S1 of trypsin. in Handbook of Proteolytic Enzymes (eds. Barrett, A.J., Rawlings, N.D. & Woessner, J.F.) 5-12 (Academic Press, London, UK, 1998).
2. Rawlings, N.D., O'Brien, E. A. & Barrett, A.J. MEROPS: the protease database. Nucleic Acids Res. 30, 343-346 (2002).
3. Bhatt, A.S. et al. Quantification of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem. 384, 257-266 (2003).
4. Hooper, J.D., Clements, J.A., Quigley, J.P. & Antalis, T.M. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276, 857-860 (2001).
5. Yousef, G.M. & Diamandis, E.P. Human tissue kallikreins: a new enzymatic cascade pathway? Biol. Chem. 383, 1045-1057 (2002).
6. Takeuchi, T., Shuman, M.A. & Craik, C.S. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96, 11054-11061 (1999).
7. Lin, C.Y., Anders, J., Johnson, M., Sang, Q.A. & Dickson, R.B. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236 (1999).
8. Kim, M.G. et al. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49, 420-428 (1999).
9. Oberst, M.D. et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8, 1101-1107 (2002).
10. Kang, J.Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63, 1101-1105 (2003).
11. Dhanasekaran, S.M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
12. Catalona, W.J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156-1161 (1991).
13. Hoffman, B.R. et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer 87, 763-771 (2002).
14. List, K. et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-3779 (2002).
15. Ebnet, K. et al. Granzyme A-deficient mice retain potent cell-mediated cytotoxicity. EMBO J. 14, 4230-4239 (1995).
16. Sanderson, P.E. Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19, 179-197 (1999).
17. Leung, D., Abbenante, G. & Fairlie, D.P. Protease inhibitors: current status and future prospects. J. Med. Chem. 43, 305-341 (2000).
18. Perona, J.J., Tsu, C.A., Craik, C.S. & Fletterick, R.J. Crystal structures of rat anionic trypsin complexed with the protein inhibitors APPI and BPTI. J. Mol. Biol. 230, 919-933 (1993).
19. Chung, C.H., Ives, H.E., Almeda, S. & Goldberg, A.L. Purification from Escherichia coli of a periplasmic protein that is a potent inhibitor of pancreatic proteases. J. Biol. Chem. 258, 11032-11038 (1983).
20. Gillmor, S.A., Takeuchi, T., Yang, S.Q., Craik, C.S. & Fletterick, R.J. Compromise and accommodation in ecotin, a dimeric macromolecular inhibitor of serine proteases. J. Mol. Biol. 299, 993-1003 (2000).
21. McGrath, M.E., Erpel, T., Bystroff, C. & Fletterick, R.J. Macromolecular chelation as an improved mechanism of protease inhibition: structure of the ecotin-trypsin complex. EMBO J. 13, 1502-1507 (1994).
22. Wang, S.X., Esmon, C.T. & Fletterick, R.J. Crystal structure of thrombin-ecotin reveals conformational changes and extended interactions. Biochemistry 40, 10038-10046 (2001).
23. Eggers, C.T., Wang, S.X., Fletterick R.J. & Craik, C.S. The role of ecotin dimerization in protease inhibition. J. Mol. Biol. 308, 975-991 (2001).
24. Seymour, J.L. et al. Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of Factor Xa. Biochemistry 33, 3949-3958 (1994).
25. Ulmer, J.S., Lindquist, R.N., Dennis, M.S. & Lazarus, R.A. Ecotin is a potent inhibitor of the contact system proteases Factor XIIa and plasma kallikrein. FEBS Lett. 365, 159-163 (1995).
26. Colman, R.W. & Schmaier, A.H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90, 3819-3843 (1997).
27. Selvarajan, S., Lund, L.R., Takeuchi, T., Craik, C.S. & Werb, Z. A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat. Cell Biol. 3, 267-275 (2001).
28. Dela Cadena, R.A. et al. Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. FASEB J. 9, 446-452 (1995).
29. Stadnicki, A. et al. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J. 12, 325-333 (1998).
30. Dennis, M.S., Herzka, A. & Lazarus, R.A. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. J. Biol. Chem. 270, 25411-25417 (1995).
31. Markland, W., Ley, A.C. & Ladner, R.C. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 35, 8058-8067 (1996).
32. Stemmer, W.P. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370, 389-391 (1994).
33. Ness, J.E. et al. Synthetic shuffling expands functional protein diversity by allowing amino acids to recombine independently. Nat. Biotechnol. 20, 1251-1255 (2002).
34. Bogan, A.A. & Thorn, K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280, 1-9 (1998).
35. Yang, S.Q. & Craik, C.S. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator. J. Mol. Biol. 279, 1001-1011 (1998).
36. Laboissiere, M.C. et al. Computer-assisted mutagenesis of ecotin to engineer its secondary binding site for urokinase inhibition. J. Biol. Chem. 277, 26623-26631 (2002).
37. McBride, J.D., Freeman, N., Domingo, G.J. & Leatherbarrow, R.J. Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library. J. Mol. Biol. 259, 819-827 (1996).
38. Dennis M.S. & Lazarus R.A. Kunitz domain inhibitors of tissue factor-Factor VIIa. I. Potent inhibitors selected from libraries by phage display. J. Biol. Chem. 269, 22129-22136 (1994).
39. Yang, S.Q., Wang, C.I., Gillmor, S.A. Fletterick, R.J. & Craik C.S. Ecotin: a serine protease inhibitor with two distinct and interacting binding sites. J. Mol. Biol. 279, 945-957 (1998).
40. Hecker, K.H. & Rill, R.L. Error analysis of chemically synthesized polynucleotides. Biotechniques 24, 256-260 (1998).
41. Chung, D.W., Fujikawa, K., McMullen, B.A. & Davie, E.W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25, 2410-2417 (1986).
42. OASIS investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 353, 429-438 (1999).
43. Cappello, M., Vlasuk, G.P., Bergum, P.W., Huang, S. & Hotez, P.J. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation Factor Xa. Proc. Natl. Acad. Sci. USA 92, 6152-6156 (1995).
44. Laroche, Y. et al. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 96, 1425-1432 (2000).
45. Barbas, C.F., Kang, A.S., Lerner, R.A. & Benkovic, S.J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88, 7978-7982 (1991).
46. Stoop, A.A., Jespers, L., Lasters, I., Eldering, E. & Pannekoek, H. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). J. Mol. Biol. 301, 1135-1147 (2000).
47. Morrison, J.F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269-286 (1969).
48. Kraulis, P.J. MolScript: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950 (1991).
49. Fujikawa, K., Chung, D.W., Hendrickson L.E. & Davie, E.W. Aminoacid sequence of human Factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 25, 2417-2424 (1986).